| Name | Title | Contact Details |
|---|
The mission of REVOLUTION Medicines is redesigning evolution`s products to treat serious diseases. The company discovers and develops new drugs by reconfiguring natural substances that are inherently rich with biological function as a result of natural selection. The company`s first drug candidates are innovative small molecules that exploit and improve upon the properties of amphotericin B, a powerful, broad-spectrum antifungal compound found in nature that has avoided generating significant drug resistance in 50 years of clinical use. Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investor Third Rock Ventures.
Bryan LGH is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The founders of NXT-ID were an integral part of the senior management teams at Technest Holdings, Inc., and its subsidiary Genex Technologies. Genex Technologies was founded in 1995 to develop and commercialize the unique Rainbow® method of capturing 3D data. Since its founding Genex has developed into one of the market leaders in advanced imaging, including 3D and 360-degree technologies. Genex has developed innovative technologies and products for all aspects of imaging, including capture, processing, display, and enhancement. Genex’s products range from 3D cameras to surveillance algorithms to integrated facial recognition systems. Genex and Technest have won awards from the Department of Defense, NIH, NIST and NSF amounting to over $30 million in support of this technology. NXT-ID has licensed all the Technest /Genex technology (exclusively in many markets) to provide a product portfolio and a strong technical foundation for its further development efforts. In addition, NXT-ID has also licensed patents and know-how from the shareholders of Geometrix, Inc., a leading 3D imaging company using a different technical approach to Technest. This technology performed very favorably at the Face Recognition Vendor Test conducted by the National Institute of Science and Technology (NIST). NXT-ID also has key scientific and engineering personnel that have had key roles in the development of these technologies and have an important intellectual knowledge base that the Company intends to leverage.
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world`s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
Nonlethal Technologies, Inc is a Homer City, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.